Response to "Liraglutide Effectiveness: Is There a Real-World Clinical Benefit?"

Obesity (Silver Spring). 2019 Nov;27(11):1728. doi: 10.1002/oby.22630. Epub 2019 Sep 23.

Authors

Sean Wharton¹, Aiden Liu², Arash Pakseresht², Emil Nørtoft³, Christiane L Haase³, Johanna Mancini⁴, G Sarah Power⁵, Sarah Vanderlelie¹, Rebecca A G Christensen¹

Affiliations

¹ Wharton Medical Clinic, Burlington, Ontario, Canada.
² Novo Nordisk Canada Inc., Mississauga, Ontario, Canada.
³ Novo Nordisk A/S, Søborg, Denmark.
⁴ IQVIA, Kirkland, Quebec, Canada.
⁵ IQVIA, Mississauga, Ontario, Canada.

PMID: 31545003
DOI: 10.1002/oby.22630

No abstract available

Publication types

Letter
Comment

MeSH terms

Canada
Glycated Hemoglobin / analysis
Hypoglycemic Agents*
Liraglutide*
Treatment Outcome

Substances

Glycated Hemoglobin A
Hypoglycemic Agents
Liraglutide